Bluebird 'Potentially The Walter White Of CAR T Therapy,' Says BTIG
After market close on Wednesday, bluebird bio Inc (NASDAQ: BLUE) released early data on the relapsed/refractory multiple myeloma study. Traders flocked to the stock after the good news, and the stock was up 22 percent after hours, spiking to $74.45 at market open Thursday, before leveling out at $71.40 mid day.
BTIG Still Says Buy
Following a conference call hosted Thursday morning to discuss the results, BTIG Equity Research analyst Dana Leone published a note maintaining the earlier stated Buy rating and $83 price target on the stock, while highlighting that the dataset hints at a bluebird and Celgene Corporation (NASDAQ: CELG) combo having an “X-factor” in manufacturing CAR T products.
In an earlier published note, the analyst highlights the strong efficacy and low toxicity points demonstrated by the early data with no obvious patient differences when compared with competitor data.
“As a result, we do think the know-how of Celgene manufacturing combined with the lentiviral tech transfer from BLUE may be an X factor supporting initially superior results versus the competition,” said Leone.
At time of writing, bluebird shares were trading up around 18 percent at $71.16.
Image Credit: By WitcherGeralt (Own work) [CC BY-SA 3.0], via Wikimedia Commons
Latest Ratings for BLUE
|Feb 2017||Roth Capital||Downgrades||Buy||Neutral|
|Nov 2016||BMO Capital||Initiates Coverage On||Market Perform|
|Oct 2016||Cantor Fitzgerald||Downgrades||Hold||Sell|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.